Regenerative Medical Technology (RMTG) Income towards Parent Company (2018 - 2025)
Historic Income towards Parent Company for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$3.9 million.
- Regenerative Medical Technology's Income towards Parent Company fell 34436.35% to -$3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year increase of 73.94%. This contributed to the annual value of -$5.6 million for FY2024, which is 2284.43% up from last year.
- According to the latest figures from Q3 2025, Regenerative Medical Technology's Income towards Parent Company is -$3.9 million, which was down 34436.35% from -$1.3 million recorded in Q2 2025.
- In the past 5 years, Regenerative Medical Technology's Income towards Parent Company registered a high of $68663.0 during Q4 2022, and its lowest value of -$9.9 million during Q3 2021.
- Moreover, its 5-year median value for Income towards Parent Company was -$758890.0 (2025), whereas its average is -$1.5 million.
- In the last 5 years, Regenerative Medical Technology's Income towards Parent Company soared by 10439.81% in 2022 and then tumbled by 39913110.6% in 2023.
- Over the past 5 years, Regenerative Medical Technology's Income towards Parent Company (Quarter) stood at -$1.6 million in 2021, then surged by 104.4% to $68663.0 in 2022, then plummeted by 2675.25% to -$1.8 million in 2023, then soared by 63.86% to -$639071.0 in 2024, then crashed by 516.01% to -$3.9 million in 2025.
- Its last three reported values are -$3.9 million in Q3 2025, -$1.3 million for Q2 2025, and -$758890.0 during Q1 2025.